Show simple item record

dc.contributor.authorCentenera, Margaret Men
dc.contributor.authorHickey, Theresa Een
dc.contributor.authorJindal, Shalinien
dc.contributor.authorRyan, Natalie Ken
dc.contributor.authorRavindranathan, Preethien
dc.contributor.authorMohammed, Hishamen
dc.contributor.authorRobinson, Jessica Len
dc.contributor.authorSchiewer, Matthew Jen
dc.contributor.authorMa, Shihongen
dc.contributor.authorKapur, Payalen
dc.contributor.authorSutherland, Peter Den
dc.contributor.authorHoffmann, Clive Een
dc.contributor.authorRoehrborn, Claus Gen
dc.contributor.authorGomella, Leonard Gen
dc.contributor.authorCarroll, Jasonen
dc.contributor.authorBirrell, Stephen Nen
dc.contributor.authorKnudsen, Karen Een
dc.contributor.authorRaj, Ganesh Ven
dc.contributor.authorButler, Lisa Men
dc.contributor.authorTilley, Wayne Den
dc.date.accessioned2019-04-25T23:30:17Z
dc.date.available2019-04-25T23:30:17Z
dc.date.issued2018-09en
dc.identifier.issn1878-0261
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/291986
dc.description.abstractBreast and prostate cancer research to date has largely been predicated on the use of cell lines in vitro or in vivo. These limitations have led to the development of more clinically relevant models, such as organoids or murine xenografts that utilize patient-derived material; however, issues related to low take rate, long duration of establishment, and the associated costs constrain use of these models. This study demonstrates that ex vivo culture of freshly resected breast and prostate tumor specimens obtained from surgery, termed patient-derived explants (PDEs), provides a high-throughput and cost-effective model that retains the native tissue architecture, microenvironment, cell viability, and key oncogenic drivers. The PDE model provides a unique approach for direct evaluation of drug responses on an individual patient's tumor, which is amenable to analysis using contemporary genomic technologies. The ability to rapidly evaluate drug efficacy in patient-derived material has high potential to facilitate implementation of personalized medicine approaches.
dc.description.sponsorshipCancer Research UK and ERC.
dc.languageengen
dc.publisherJohn Wiley and Sons Inc.
dc.rightsAttribution 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subjectex vivo cultureen
dc.subjectpatient-derived explanten
dc.subjectpreclinical tumor modelen
dc.titleA patient-derived explant (PDE) model of hormone-dependent cancer.en
dc.typeArticle
prism.endingPage1622
prism.issueIdentifier9en
prism.publicationDate2018en
prism.publicationNameMolecular Oncologyen
prism.startingPage1608
prism.volume12en
dc.identifier.doi10.17863/CAM.39139
dcterms.dateAccepted2018-06-25en
rioxxterms.versionofrecord10.1002/1878-0261.12354en
rioxxterms.versionVoR
rioxxterms.licenseref.urihttp://creativecommons.org/licenses/by/4.0/en
rioxxterms.licenseref.startdate2018-09en
dc.contributor.orcidCarroll, Jason [0000-0003-3643-0080]
dc.identifier.eissn1878-0261
rioxxterms.typeJournal Article/Reviewen
pubs.funder-project-idCancer Research UK (C14303_do not transfer)
cam.issuedOnline2018-08-16en


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 International
Except where otherwise noted, this item's licence is described as Attribution 4.0 International